Do uterine leiomyomas affect fetal growth and delivery outcomes during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Uterine Leiomyomas and Pregnancy Outcomes

Yes, uterine leiomyomas (fibroids) significantly affect pregnancy outcomes, with the impact heavily dependent on fibroid location and size—submucosal and intramural fibroids increase risks of preterm delivery, placental abruption, and cesarean delivery, while subserosal fibroids have minimal impact on pregnancy outcomes.

Impact on Fetal Growth

The evidence shows that leiomyomas do not typically cause intrauterine growth restriction (IUGR) in term pregnancies 1, 2. When low birth weight occurs in pregnancies complicated by fibroids, it is primarily due to preterm delivery rather than growth restriction 1. One study specifically found that fibroids did not significantly alter the incidence of intrauterine growth retardation 2.

However, there is a critical exception: retroplacental fibroids (those located beneath the placenta) carry substantially higher risks, with one study showing 57% of patients with retroplacental leiomyomas developed placental abruption, resulting in four fetal deaths 2. This represents a dramatically elevated risk compared to the 2.5% abruption rate when fibroids are not retroplacental.

Impact on Delivery Outcomes

Preterm Delivery Risk

Pregnant women with leiomyomas face significantly increased risks of preterm birth 1, 3:

  • 1.7-fold increased risk of delivery before 34 weeks (adjusted OR 1.7,95% CI 1.1-2.6)
  • 1.9-fold increased risk before 32 weeks (adjusted OR 1.9,95% CI 1.2-3.2)
  • 2.0-fold increased risk before 28 weeks (adjusted OR 2.0,95% CI 1.1-3.8)

The risk of premature labor correlates positively with the size of the largest myoma, occurring in 21.5% of patients with fibroids 2.

Cesarean Delivery

The presence of uterine leiomyomas dramatically increases cesarean delivery rates, with a 6.7-fold increased risk (OR 6.7,95% CI 5.5-8.1) compared to pregnancies without fibroids 3. This elevated rate persists even after adjusting for maternal age, parity, gestational age, and malpresentation.

Other Delivery Complications

Pregnancies with fibroids are associated with 4, 3:

  • Placental abruption: 2.6-fold increased risk (OR 2.6,95% CI 1.6-4.2)
  • Abnormal fetal presentation in labor
  • Pelvic outlet obstruction
  • Postpartum hemorrhage
  • Puerperal sepsis

Perinatal Mortality

The data on perinatal mortality shows nuanced findings. While crude rates appear elevated (2.2% vs 1.2%), after controlling for confounders including maternal age, parity, and gestational age, the difference in perinatal mortality is not statistically significant (OR 1.4,95% CI 0.7-2.8) 3.

However, intrauterine fetal demise (IUFD) risk is significantly elevated at earlier gestational ages, with a 4.2-fold increased risk before 32 weeks (OR 4.2,95% CI 1.2-14.7), though not after 32 weeks 1.

Location-Specific Effects

The type and location of fibroids critically determine pregnancy outcomes 4, 5:

  • Submucosal (SM) fibroids: Associated with increased risks of spontaneous abortion, preterm delivery, and significantly reduced implantation rates (4.3% vs 15.7% in controls)

  • Intramural (IM) fibroids: Even without cavity distortion, these reduce pregnancy rates (16.4% vs 30.1% in controls) and implantation rates (6.4% vs 15.7%)

  • Subserosal (SS) fibroids: Pregnancy and implantation rates are NOT influenced by subserosal fibroids (34.1% pregnancy rate, comparable to 30.1% in controls) 4

Clinical Management Implications

Women with leiomyomas constitute a high-risk obstetric group requiring specialized management 6, 7:

  1. Preconception counseling should address fibroid characteristics (type, size, location, number) as these determine pregnancy risk stratification 5

  2. Surgical or medical treatment should be considered for intramural and submucosal fibroids before attempting conception, particularly for those undergoing assisted reproductive technology 4

  3. During pregnancy, women with fibroids require closer monitoring, particularly those with:

    • Retroplacental fibroids (highest risk for abruption)
    • Large fibroids (increased risk of pain requiring narcotics in 15.1% and premature labor in 21.5%)
    • Multiple fibroids
  4. Hospitalization in specialized obstetrical facilities is recommended during high-risk pregnancy periods 6

Important Caveats

  • Passive surveillance is not advisable for women of childbearing age with uterine leiomyomas 6
  • The clinical significance depends heavily on fibroid characteristics—size, position, and number all matter 4, 5, 2
  • Most fibroids are asymptomatic and require no intervention 7
  • Hysteroscopic myomectomy for submucosal fibroids does not appear to reduce preterm delivery rates or other adverse obstetrical outcomes, though it may improve fertility 8, 9

4, 1, 5, 3, 2, 6, 7

References

Research

Neonatal outcomes in women with sonographically identified uterine leiomyomata.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2012

Research

The clinical significance of uterine leiomyomas in pregnancy.

American journal of obstetrics and gynecology, 1989

Research

The differences in characteristics of uterine leiomyomas and the diverse adverse pregnancy outcomes.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2021

Research

Uterine Leiomyoma in women of reproductive age: A systematic review.

Wiadomosci lekarskie (Warsaw, Poland : 1960), 2025

Research

Guideline No. 461: The Management of Uterine Fibroids.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2025

Related Questions

Can a 39-year-old woman with an 8 × 8 cm uterine fibroid, who had a miscarriage one month ago and has a serum β‑hCG of 844 mIU/mL, safely undergo medical management of the fibroid with leuprolide (Lupron) while preserving the uterus?
For a 41-year-old woman with type 2 diabetes mellitus, chronic iron‑deficiency anemia, dyslipidemia, anxiety, dysmenorrhea, and abnormal uterine bleeding due to intramural uterine fibroids, who is currently on metformin, atorvastatin, Depo‑Provera (depot medroxyprogesterone acetate), and iron supplementation, what additional management steps should be taken?
What is the most effective therapy for a 52-year-old woman who had a hysterectomy for uterine fibroids and now experiences frequent hot flashes lasting 3–5 minutes, occurring 5–10 times daily for the past 5 months?
In a 60-year-old woman with multiple uterine fibroids who complains of cramping, what is the appropriate treatment approach?
In a 37-year-old pregnant woman with three uterine fibroids, what activity restrictions are recommended and which exercises are safe?
What is the appropriate workup and management for an adult patient with anorexia and severe weight loss (BMI < 17 kg/m²)?
Can I donate blood after a history of hepatitis A?
What are the risk factors for Parkinson's disease?
What is the optimal management strategy for pancreatic cancer presenting with obstructive jaundice and partial portal vein involvement?
How are orthostatic vital signs measured?
Which bacterial vaccine, UroVaxom (OM‑89) or Solco‑Urovac/Strovac, is more effective for preventing recurrent urinary tract infections according to research?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.